Estados Unidos · Plataformas y datos · MarketBeat
Axsome Therapeutics Sees AUVELITY Prescription Surge After Alzheimer’s Agitation Launch

Resumen detallado
Axsome Therapeutics (NASDAQ:AXSM) executives said growth in new prescriptions for AUVELITY and an expanded sales team are positioning the company for further growth following the drug’s launch for Alzheimer’s disease agitation. Speaking at the UBS Biopharma Conference in London, Chief Financial Off
MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.marketbeat.com)




